文献速递乳腺癌放疗放疗物理与技术

VMAT用于26 Gy/5次超低分次全乳放疗的剂量学与毒性

Volumetric Modulated Arc Therapy for 26 Gy in 5 Fractions Whole Breast Irradiation for Breast Cancer.
PubMed 文献 · Adv Radiat Oncol · 2025-02-01

该研究报告476例2020—2021年接受VMAT超低分次(26 Gy/5次)全乳放疗患者的急性毒性与剂量学结果,并与同机构392例3D-CRT中度低分次(总剂量换算为26 Gy)历史队列比较。VMAT组靶区覆盖与均匀性更优,危及器官剂量总体相近,但同侧肺、心脏差异<0.3 Gy,左前降支Dmax更低而对侧乳腺Dmean更高;急性毒性以1级为主。

要点

  • VMAT超低分次全乳放疗靶区覆盖与均匀性优于3D-CRT,危及器官剂量总体保持较低。
  • 与3D-CRT相比,VMAT组左前降支Dmax降低3.73 Gy,但对侧乳腺Dmean升高1.43 Gy。
  • 急性毒性以1级为主(120例中114例),中位随访21.2个月未见其他毒性。

核心结论

  • VMAT用于超低分次全乳放疗可改善靶区覆盖并保持危及器官剂量较低,但与3D-CRT相比对侧乳腺剂量增加;作者认为这些剂量学差异的临床意义需进一步研究。

研究设计与样本

  • 单机构连续病例系列,纳入2020—2021年接受VMAT超低分次(26 Gy/5次)全乳放疗的476例患者,并与同机构392例3D-CRT中度低分次历史队列比较(总剂量换算为26 Gy)。

主要发现

  • VMAT组PTV的D95%均值为处方剂量的96.2%,Dmax均值为102.8%。
  • 与3D-CRT组相比,VMAT组D95高30.6%、Dmax低0.7%(均P<.05)。
  • 同侧肺与心脏平均剂量分别为3.12±4.59 Gy和0.92±0.25 Gy,与3D-CRT组差异<0.3 Gy。
  • 与3D-CRT组相比,VMAT组左前降支Dmax降低3.73 Gy,对侧乳腺Dmean升高1.43 Gy。
  • VMAT组急性毒性以轻度为主,120例中114例为1级;中位随访21.2个月未见其他毒性。

关键数值与推荐

  • 处方剂量为26 Gy分5次(超低分次)全乳放疗。
  • VMAT组PTV D95%均值96.2%、Dmax均值102.8%(均为处方剂量百分比)。
  • VMAT组同侧肺平均剂量3.12±4.59 Gy,心脏平均剂量0.92±0.25 Gy。
  • 与3D-CRT组相比:D95高30.6%、Dmax低0.7%(均P<.05);左前降支Dmax降低3.73 Gy;对侧乳腺Dmean升高1.43 Gy。

临床怎么用

  • 对于接受26 Gy/5次超低分次全乳放疗的患者,VMAT可改善靶区覆盖与均匀性并保持危及器官剂量较低。
  • 采用VMAT时需注意对侧乳腺剂量较3D-CRT升高,左前降支Dmax可降低。
  • 该队列急性毒性以1级为主,但剂量学差异的临床意义仍需进一步研究。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the dosimetric and toxicity outcomes of patients treated with 26 Gy in 5 fractions ultrahypofractionated (uHF) whole breast irradiation (WBI) using volumetric arc therapy (VMAT). METHODS AND MATERIALS: We identified 476 consecutive patients who underwent WBI using VMAT-uHF between 2020 and 2021. Study endpoints included acute toxicity and dosimetric parameters for target volume and organs at risk. The dosimetric results were compared with a historical cohort at the same institution who were treated with moderately hypofractionated WBI using 3-dimensional (3D)-conformal radiation therapy (3D-CRT, n = 392), with the total dose rescaled to 26 Gy. RESULTS: VMAT-uHF achieved a mean D95% and Dmax of the planning target volume of 96.2% and 102.8% of the prescribed dose, respectively. The VMAT-uHF group demonstrated significantly superior planning target volume coverage and improved dose homogeneity, with a 30.6% higher D95 and a 0.7% lower Dmax compared with the 3D-CRT group (both P < .05). Mean doses for the ipsilateral lung and heart were 3.12 ± 4.59 Gy and 0.92 ± 0.25 Gy, respectively, showing differences of < 0.3 Gy compared with the 3D-CRT group. The VMAT-uHF group exhibited a significantly lower left anterior descending artery Dmax (-3.73 Gy), while the contralateral breast showed a higher Dmean (+1.43 Gy), compared with the 3D-CRT group. Acute toxicity following VMAT-uHF was predominantly mild, with grade 1 toxicity observed in 114 out of 120 patients. No additional toxicities were reported after a median follow-up of 21.2 months. CONCLUSIONS: The application of VMAT in ultrahypofractionation can enhance target coverage while maintaining radiation doses to organs at risk low, albeit with an increase in contralateral breast dose compared with 3D-CRT. Given the low toxicity profile observed in our cohort with VMAT-uHF, the clinical significance of these dosimetric differences requires further investigation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Choi SH, Kim JS, Kim HJ, et al. Volumetric Modulated Arc Therapy for 26 Gy in 5 Fractions Whole Breast Irradiation for Breast Cancer. Adv Radiat Oncol. 2025. PMID: 40161543. doi:10.1016/j.adro.2025.101733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。